risperidone has been researched along with Chronic Motor and Vocal Tic Disorder in 48 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the efficacy and safety of risperidone in children and adults with Tourette syndrome." | 9.10 | A placebo-controlled trial of risperidone in Tourette syndrome. ( Katsovich, L; Leckman, JF; Peterson, BS; Scahill, L; Schultz, RT, 2003) |
| "A double-blind, placebo-controlled trial was performed to determine the efficacy and tolerability of 8 weeks of treatment with risperidone in the management of 48 adolescent and adult patients with Tourette syndrome." | 9.10 | Risperidone in the treatment of tourette syndrome: a double-blind, placebo-controlled trial. ( Annable, L; Chouinard, G; Dion, Y; Sandor, P, 2002) |
| "To evaluate the efficacy and harms of pimozide in comparison to placebo or other medications in the treatment of tics in Tourette Syndrome." | 8.85 | Pimozide for tics in Tourette's syndrome. ( Marras, C; Pringsheim, T, 2009) |
| "MDD and dysphoria commonly occurred in this cohort of adult and adolescent Tourette's disorder patients treated with risperidone, particularly in patients with a previous history of depression." | 7.71 | Depression and dysphoria in adult and adolescent patients with Tourette's disorder treated with risperidone. ( Annable, L; Dion, Y; Margolese, HC, 2002) |
| "To evaluate the efficacy and safety of risperidone in children and adults with Tourette syndrome." | 5.10 | A placebo-controlled trial of risperidone in Tourette syndrome. ( Katsovich, L; Leckman, JF; Peterson, BS; Scahill, L; Schultz, RT, 2003) |
| "A double-blind, placebo-controlled trial was performed to determine the efficacy and tolerability of 8 weeks of treatment with risperidone in the management of 48 adolescent and adult patients with Tourette syndrome." | 5.10 | Risperidone in the treatment of tourette syndrome: a double-blind, placebo-controlled trial. ( Annable, L; Chouinard, G; Dion, Y; Sandor, P, 2002) |
| "To evaluate the efficacy and harms of pimozide in comparison to placebo or other medications in the treatment of tics in Tourette Syndrome." | 4.85 | Pimozide for tics in Tourette's syndrome. ( Marras, C; Pringsheim, T, 2009) |
| "A patient with Gilles de la Tourette syndrome treated with haloperidol, ingested once daily after awakening from sleep, exhibited an irregular sleep-wake pattern with a free-running component of approximately 48 h." | 3.71 | Case study of circadian rhythm sleep disorder following haloperidol treatment: reversal by risperidone and melatonin. ( Ayalon, L; Dagan, Y; Hermesh, H, 2002) |
| "MDD and dysphoria commonly occurred in this cohort of adult and adolescent Tourette's disorder patients treated with risperidone, particularly in patients with a previous history of depression." | 3.71 | Depression and dysphoria in adult and adolescent patients with Tourette's disorder treated with risperidone. ( Annable, L; Dion, Y; Margolese, HC, 2002) |
| "A 15-year-old adolescent male, with Asperger's disorder, Tourette's disorder and obsessive-compulsive disorder, on a tetracycline-risperidone-sertraline treatment regimen, had an acute exacerbation of motor and vocal tics." | 3.70 | A possible tetracycline-risperidone-sertraline interaction in an adolescent. ( Couturier, J; Steele, M, 1999) |
| "A series of patients with OCD (N = 8), trichotillomania (N = 5), and Tourette's syndrome (N = 3) who were refractory to treatment with serotonin reuptake inhibitors had received risperidone augmentation." | 3.69 | Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disorders. ( Bouwer, C; Emsley, RA; Hawkridge, S; Stein, DJ, 1997) |
| "Our analyses show that antipsychotic drugs are the most efficacious intervention for Tourette's syndrome, while α-2 agonists are also more efficacious than placebo and could be chosen by those who elect not to take antipsychotic drugs." | 3.01 | Comparative efficacy, tolerability, and acceptability of pharmacological interventions for the treatment of children, adolescents, and young adults with Tourette's syndrome: a systematic review and network meta-analysis. ( Behling, E; Bloch, MH; Farhat, LC; Landeros-Weisenberger, A; Levine, JLS; Macul Ferreira de Barros, P; Wang, Z, 2023) |
| "The treatment of Tourette's disorder with classical neuroleptics is limited by their side effects." | 2.70 | Risperidone versus pimozide in Tourette's disorder: a comparative double-blind parallel-group study. ( Bruggeman, R; Buitelaar, JK; Gericke, GS; Hawkridge, SM; Temlett, JA; van der Linden, C, 2001) |
| "Thirty-eight patients with Tourette's syndrome volunteered to take risperidone for treatment of their tics." | 2.68 | Risperidone as a treatment for Tourette's syndrome. ( Bruun, RD; Budman, CL, 1996) |
| "We reviewed articles in English dealing with research into the effect of atypical antipsychotic drugs on tic reduction in Tourette's syndrome." | 2.41 | [Treatment of tics in Tourette syndrome with atypical antipsychotic drugs]. ( Jørgensen, JI; Sindø, I, 2002) |
| "Medications used in the treatment of Tourette's syndrome are thought to modulate the functioning of these neural systems." | 2.39 | Considerations of natural history and pathophysiology in the psychopharmacology of Tourette's syndrome. ( Peterson, BS, 1996) |
| "We herein report a case of Tourette's syndrome, in which time estimation was differentially affected by risperidone (a DA antagonist) and aripiprazole (a DA partial agonist)." | 1.56 | Time estimation in a case of Tourette's syndrome: Effect of antipsychotic medications. ( Inagawa, T; Nakagome, K; Sumiyoshi, T; Ueda, N, 2020) |
| "Risperidone and clonidine were the most commonly recommended medications for tic disorders over the study period, with 36,868 and 35,500 recommendations in 2016, respectively." | 1.51 | Prescriptions for Alpha Agonists and Antipsychotics in Children and Youth with Tic Disorders: A Pharmacoepidemiologic Study. ( Cothros, N; Martino, D; McMorris, C; Pringsheim, T; Stewart, D; Tehrani, A, 2019) |
| "We used a systematic survey to collate the consensus of Japanese experts and compare it with the recent international evidence." | 1.51 | Expert consensus on pharmacotherapy for tic disorders in Japan. ( Fujio, M; Hamamoto, Y; Kano, Y; Kono, T; Matsuda, N; Nonaka, M, 2019) |
| "The child was diagnosed with Tourette's syndrome at 7 years of age when he suffered from tics and experienced his first manic episode." | 1.35 | Diagnosis and treatment of comorbidities of Tourette's syndrome and bipolar disorder in a 10-year-old boy. ( Huang, MF; Huang, RR; Wang, PW; Yen, CF, 2009) |
| " The mean dosage of risperidone was 0." | 1.33 | Effectiveness and safety of risperidone for children and adolescents with chronic tic or tourette disorders in Korea. ( Cho, SC; Hwang, JW; Kim, BN; Lee, CB; Shin, MS, 2005) |
| "Ritonavir and indinavir were initiated, and 1 week later, he experienced significantly impaired swallowing, speaking, and breathing, and worsening of his existing tremors." | 1.31 | Extrapyramidal symptoms with ritonavir/indinavir plus risperidone. ( Béïque, LC; Bowmer, MI; Kelly, DV, 2002) |
| "The sample included five patients with Tourette's syndrome and two with chronic motor tic disorder." | 1.29 | Risperidone treatment of children and adolescents with chronic tic disorders: a preliminary report. ( Chappell, PB; King, RA; Leckman, JF; Lombroso, PJ; Lynch, KA; McDougle, CJ; Peterson, BS; Scahill, L, 1995) |
| "Erythromycin would inhibit demethylation of clomipramine at the 1A2 isoenzyme and lead to a dual interaction between risperidone and clomipramine at the CYP2D6 isoenzyme." | 1.29 | Erythromycin interaction with risperidone or clomipramine in an adolescent. ( Diaz, P; Fisman, S; Reniers, D, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 12 (25.00) | 18.2507 |
| 2000's | 23 (47.92) | 29.6817 |
| 2010's | 10 (20.83) | 24.3611 |
| 2020's | 3 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Roessner, V | 2 |
| Eichele, H | 1 |
| Stern, JS | 1 |
| Skov, L | 1 |
| Rizzo, R | 1 |
| Debes, NM | 1 |
| Nagy, P | 1 |
| Cavanna, AE | 2 |
| Termine, C | 1 |
| Ganos, C | 1 |
| Münchau, A | 2 |
| Szejko, N | 1 |
| Cath, D | 1 |
| Müller-Vahl, KR | 1 |
| Verdellen, C | 1 |
| Hartmann, A | 2 |
| Rothenberger, A | 1 |
| Hoekstra, PJ | 1 |
| Plessen, KJ | 1 |
| Farhat, LC | 2 |
| Behling, E | 2 |
| Landeros-Weisenberger, A | 2 |
| Levine, JLS | 2 |
| Macul Ferreira de Barros, P | 2 |
| Wang, Z | 2 |
| Bloch, MH | 2 |
| Cothros, N | 1 |
| Martino, D | 1 |
| McMorris, C | 1 |
| Stewart, D | 1 |
| Tehrani, A | 1 |
| Pringsheim, T | 3 |
| Inagawa, T | 1 |
| Ueda, N | 1 |
| Nakagome, K | 1 |
| Sumiyoshi, T | 1 |
| Ho, J | 1 |
| Sarna, JR | 1 |
| Hammer, T | 1 |
| Patten, S | 1 |
| Hamamoto, Y | 1 |
| Fujio, M | 1 |
| Nonaka, M | 1 |
| Matsuda, N | 1 |
| Kono, T | 1 |
| Kano, Y | 1 |
| Chovaz, CJ | 1 |
| Sarı, BA | 1 |
| Taşkıntuna, N | 1 |
| Yalçın, Ö | 1 |
| Budman, CL | 2 |
| Arana-Lechuga, Y | 1 |
| Sanchez-Escandón, O | 1 |
| de Santiago-Treviño, N | 1 |
| Castillo-Montoya, C | 1 |
| Terán-Pérez, G | 1 |
| Velázquez-Moctezuma, J | 1 |
| Boarati, MA | 1 |
| Castillo, AR | 1 |
| Castillo, JC | 1 |
| Fu-I, L | 1 |
| Marras, C | 1 |
| Degrauw, RS | 1 |
| Li, JZ | 1 |
| Gilbert, DL | 1 |
| Palminteri, S | 1 |
| Lebreton, M | 1 |
| Worbe, Y | 1 |
| Grabli, D | 1 |
| Pessiglione, M | 1 |
| Wang, PW | 1 |
| Huang, MF | 1 |
| Yen, CF | 1 |
| Huang, RR | 1 |
| Hebebrand, J | 1 |
| Rickards, H | 1 |
| Worrall, R | 1 |
| Nakamae, T | 1 |
| Cheng, W | 1 |
| Lin, L | 1 |
| Guo, S | 1 |
| Schoenefeld, K | 1 |
| Buse, J | 1 |
| Bender, S | 1 |
| Ehrlich, S | 1 |
| Valdovinos, MG | 1 |
| Napolitano, DA | 1 |
| Zarcone, JR | 1 |
| Hellings, JA | 1 |
| Williams, DC | 1 |
| Schroeder, SR | 1 |
| Sindø, I | 1 |
| Jørgensen, JI | 1 |
| Ayalon, L | 1 |
| Hermesh, H | 1 |
| Dagan, Y | 1 |
| Margolese, HC | 1 |
| Annable, L | 2 |
| Dion, Y | 2 |
| Scahill, L | 2 |
| Leckman, JF | 2 |
| Schultz, RT | 1 |
| Katsovich, L | 1 |
| Peterson, BS | 3 |
| Gabbay, V | 1 |
| Coffey, B | 1 |
| Benjamin, E | 1 |
| Salek, S | 1 |
| Kim, BN | 1 |
| Lee, CB | 1 |
| Hwang, JW | 1 |
| Shin, MS | 1 |
| Cho, SC | 1 |
| Doneray, H | 1 |
| Tan, H | 1 |
| Orbak, Z | 1 |
| McNicholas, F | 1 |
| Motala, F | 1 |
| McDougle, CJ | 2 |
| Goodman, WK | 1 |
| Price, LH | 1 |
| Stamenkovic, M | 1 |
| Aschauer, H | 1 |
| Kasper, S | 1 |
| van der Linden, C | 2 |
| Bruggeman, R | 2 |
| van Woerkom, TC | 1 |
| Giakas, WJ | 1 |
| Shulman, LM | 1 |
| Singer, C | 1 |
| Weiner, WJ | 1 |
| Lombroso, PJ | 1 |
| King, RA | 1 |
| Lynch, KA | 1 |
| Chappell, PB | 1 |
| Bruun, RD | 1 |
| Diantoniis, MR | 1 |
| Henry, KM | 1 |
| Partridge, PA | 1 |
| Soucar, E | 1 |
| Stein, DJ | 1 |
| Bouwer, C | 1 |
| Hawkridge, S | 1 |
| Emsley, RA | 1 |
| Fisman, S | 1 |
| Reniers, D | 1 |
| Diaz, P | 1 |
| Steele, M | 1 |
| Couturier, J | 1 |
| Sandor, P | 2 |
| Stephens, RJ | 1 |
| Buitelaar, JK | 1 |
| Gericke, GS | 1 |
| Hawkridge, SM | 1 |
| Temlett, JA | 1 |
| Keck, PE | 1 |
| McElroy, SL | 1 |
| Arnold, LM | 1 |
| Chouinard, G | 1 |
| Gaffney, GR | 1 |
| Perry, PJ | 1 |
| Lund, BC | 1 |
| Bever-Stille, KA | 1 |
| Arndt, S | 1 |
| Kuperman, S | 1 |
| Kelly, DV | 1 |
| Béïque, LC | 1 |
| Bowmer, MI | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Severe Aberrant Behavior Among Persons With Mental Retardation. Project III: Behavioral Selectivity of Atypical Neuroleptic Drugs: Effects on Cognitive and Social Behaviors[NCT00065273] | Phase 3 | 50 participants | Interventional | 1998-07-31 | Completed | ||
| Transcranial Magnetic Stimulation for Individuals With Tourette's Syndrome[NCT00529308] | Phase 2 | 20 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| Behavioral Therapy for Children and Adolescents With Tourette Syndrome: A Randomized Controlled Trial in Taiwan[NCT03621059] | 46 participants (Actual) | Interventional | 2015-01-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The CGI-I is a clinician-rated scales that have been used in clinical trials for over 25 years. Clinicians rate patient improvement compared to baseline. By convention, 4 = No Change; scores of 5, 6, and 7 move in the direction of worsening; scores of 3, 2, and 1 correspond to Minimal Improvement, Much Improved or Very Much Improved, respectively. CGI-I ratings of Much or Very Much Improved at post-treatment are used to identify treatment responders." (NCT00529308)
Timeframe: 3 weeks
| Intervention | participants (Number) |
|---|---|
| Active | 2 |
| Sham | 8 |
"The CGI-I is a clinician-rated scales that have been used in clinical trials for over 25 years. Clinicians rate patient improvement compared to baseline. By convention, 4 = No Change; scores of 5, 6, and 7 move in the direction of worsening; scores of 3, 2, and 1 correspond to Minimal Improvement, Much Improved or Very Much Improved, respectively. CGI-I ratings of Much or Very Much Improved at post-treatment are used to identify treatment responders." (NCT00529308)
Timeframe: 3 weeks
| Intervention | participants (Number) |
|---|---|
| Active | 1 |
| Sham | 0 |
Motor Threshold (MT) is thought to be a measure of membrane excitability in pyramidal neurons. MT is defined as the minimum magnetic flux needed to elicit a threshold EMG response (50 µV in peak to peak amplitude) in a resting target muscle in 5 out of 10 trials using single pulse TMS administered to the contralateral primary motor cortex. MT for both right and left hand are determined, and the lowest is used to select the intensity for rTMS. (NCT00529308)
Timeframe: 3 weeks
| Intervention | µV (Mean) |
|---|---|
| Active | 56.5 |
| Sham | 63.8 |
Motor Threshold (MT) is thought to be a measure of membrane excitability in pyramidal neurons. MT is defined as the minimum magnetic flux needed to elicit a threshold EMG response (50 µV in peak to peak amplitude) in a resting target muscle in 5 out of 10 trials using single pulse TMS administered to the contralateral primary motor cortex. MT for both right and left hand are determined, and the lowest is used to select the intensity for rTMS. (NCT00529308)
Timeframe: 3 weeks
| Intervention | µV (Mean) |
|---|---|
| Active | 56 |
| Sham | 59.8 |
Y-GTSS is a clinician-rated scale used to assess tic severity. Motor and phonic tics are rated separately from 0 to 5 on several scales including number, frequency, intensity, complexity, and interference. Thus Motor and Phonic Tic scores can range from 0 to 25; the combined Total Tic Score ranges from 0 to 50. There is also an Impairment score that rates the overall burden due to tics. The Impairment scale yields a single score from 0 to 50 with higher scores indicating higher levels of overall impairment associated with tics. (NCT00529308)
Timeframe: 3 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Active | 29.5 |
| Sham | 31.5 |
12 reviews available for risperidone and Chronic Motor and Vocal Tic Disorder
| Article | Year |
|---|---|
European clinical guidelines for Tourette syndrome and other tic disorders-version 2.0. Part III: pharmacological treatment.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Child; Female; Guanfacine; Humans; Male; Rispe | 2022 |
Comparative efficacy, tolerability, and acceptability of pharmacological interventions for the treatment of children, adolescents, and young adults with Tourette's syndrome: a systematic review and network meta-analysis.
Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Antipsychotic Agents; Aripiprazole; Child; Clonidi | 2023 |
Comparative efficacy, tolerability, and acceptability of pharmacological interventions for the treatment of children, adolescents, and young adults with Tourette's syndrome: a systematic review and network meta-analysis.
Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Antipsychotic Agents; Aripiprazole; Child; Clonidi | 2023 |
Comparative efficacy, tolerability, and acceptability of pharmacological interventions for the treatment of children, adolescents, and young adults with Tourette's syndrome: a systematic review and network meta-analysis.
Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Antipsychotic Agents; Aripiprazole; Child; Clonidi | 2023 |
Comparative efficacy, tolerability, and acceptability of pharmacological interventions for the treatment of children, adolescents, and young adults with Tourette's syndrome: a systematic review and network meta-analysis.
Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Antipsychotic Agents; Aripiprazole; Child; Clonidi | 2023 |
The role of atypical antipsychotics for treatment of Tourette's syndrome: an overview.
Topics: Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Humans; Isoxazoles; Paliperidone Palmi | 2014 |
Pimozide for tics in Tourette's syndrome.
Topics: Anti-Dyskinesia Agents; Haloperidol; Humans; Pimozide; Randomized Controlled Trials as Topic; Risper | 2009 |
[Neuroleptic adverse effects with emphasis on weight gain].
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Brain; Cardiomyopathies; Child; Clozapine; Dyskin | 2009 |
[Diversity of obsessive-compulsive disorder and pharmacotherapy associated with obsessive-compulsive spectrum disorders].
Topics: Antipsychotic Agents; Autistic Disorder; Body Dysmorphic Disorders; Clomipramine; Comorbidity; Disru | 2011 |
[A Meta-analysis of the effectiveness of risperidone versus traditional agents for Tourette's syndrome].
Topics: Antipsychotic Agents; Humans; Randomized Controlled Trials as Topic; Risperidone; Tourette Syndrome | 2012 |
Pharmacological treatment of tic disorders and Tourette Syndrome.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivi | 2013 |
[Treatment of tics in Tourette syndrome with atypical antipsychotic drugs].
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Dopamine Antagonists; Humans; Olanzapine; Pirenzep | 2002 |
Dopamine antagonists in tic-related and psychotic spectrum obsessive compulsive disorder.
Topics: Adult; Antipsychotic Agents; Clinical Trials as Topic; Clomipramine; Clozapine; Dopamine Antagonists | 1994 |
Considerations of natural history and pathophysiology in the psychopharmacology of Tourette's syndrome.
Topics: Adolescent; Adult; Age of Onset; Antipsychotic Agents; Child; Clozapine; Disease Progression; Diseas | 1996 |
Ziprasidone: a new atypical antipsychotic.
Topics: Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Dibenzothiazepines; Dopamine Antago | 2001 |
7 trials available for risperidone and Chronic Motor and Vocal Tic Disorder
| Article | Year |
|---|---|
Multimodal evaluation of risperidone for destructive behavior: functional analysis, direct observations, rating scales, and psychiatric impressions.
Topics: Adult; Aggression; Antipsychotic Agents; Autistic Disorder; Coffin-Lowry Syndrome; Cross-Over Studie | 2002 |
A placebo-controlled trial of risperidone in Tourette syndrome.
Topics: Adolescent; Adult; Antipsychotic Agents; Body Weight; Child; Diagnostic Techniques, Neurological; Do | 2003 |
Risperidone as a treatment for Tourette's syndrome.
Topics: Adult; Child; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Patient Dropouts; Psy | 1996 |
Tics and risperidone.
Topics: Adolescent; Antipsychotic Agents; Child; Female; Humans; Male; Risperidone; Tic Disorders; Tourette | 1996 |
Risperidone versus pimozide in Tourette's disorder: a comparative double-blind parallel-group study.
Topics: Adolescent; Adult; Age of Onset; Antipsychotic Agents; Anxiety Disorders; Attention Deficit Disorder | 2001 |
Risperidone versus pimozide in Tourette's disorder: a comparative double-blind parallel-group study.
Topics: Adolescent; Adult; Age of Onset; Antipsychotic Agents; Anxiety Disorders; Attention Deficit Disorder | 2001 |
Risperidone versus pimozide in Tourette's disorder: a comparative double-blind parallel-group study.
Topics: Adolescent; Adult; Age of Onset; Antipsychotic Agents; Anxiety Disorders; Attention Deficit Disorder | 2001 |
Risperidone versus pimozide in Tourette's disorder: a comparative double-blind parallel-group study.
Topics: Adolescent; Adult; Age of Onset; Antipsychotic Agents; Anxiety Disorders; Attention Deficit Disorder | 2001 |
Risperidone in the treatment of tourette syndrome: a double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug-Induced; | 2002 |
Risperidone versus clonidine in the treatment of children and adolescents with Tourette's syndrome.
Topics: Adrenergic alpha-Agonists; Antipsychotic Agents; Child; Clonidine; Double-Blind Method; Female; Huma | 2002 |
29 other studies available for risperidone and Chronic Motor and Vocal Tic Disorder
| Article | Year |
|---|---|
Prescriptions for Alpha Agonists and Antipsychotics in Children and Youth with Tic Disorders: A Pharmacoepidemiologic Study.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Child; Child, Preschool; Female; Guanfacine; Humans; | 2019 |
Time estimation in a case of Tourette's syndrome: Effect of antipsychotic medications.
Topics: Adult; Antipsychotic Agents; Humans; Male; Risperidone; Time Perception; Tourette Syndrome | 2020 |
Feasibility and Relevance of Antipsychotic Safety Monitoring in Children With Tourette Syndrome: A Prospective Longitudinal Study.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Body Mass Index; Child; Drug | 2017 |
Expert consensus on pharmacotherapy for tic disorders in Japan.
Topics: Adult; Aged; Aripiprazole; Attention Deficit Disorder with Hyperactivity; Comorbidity; Consensus; Dr | 2019 |
Report of a deaf child with Tourette's disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Female; Humans; Language Development; Par | 2013 |
Risperidone treatment in a case of Tourette syndrome with factor V Leiden heterozygous mutation.
Topics: Antipsychotic Agents; Child; Factor V; Heterozygote; Humans; Mutation; Risperidone; Tourette Syndrom | 2014 |
Risperidone treatment of sleep disturbances in Tourette's syndrome.
Topics: Antipsychotic Agents; Child; Electroencephalography; Humans; Male; Neuropsychological Tests; Risperi | 2008 |
[Gilles de la Tourette syndrome in a child with bipolar disorder].
Topics: Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Child; Drug Therapy, Combination; Humans; | 2008 |
Body mass index changes and chronic neuroleptic drug treatment for Tourette syndrome.
Topics: Adolescent; Adolescent Development; Age Factors; Analysis of Variance; Antipsychotic Agents; Body Co | 2009 |
Pharmacological modulation of subliminal learning in Parkinson's and Tourette's syndromes.
Topics: Adolescent; Adult; Avoidance Learning; Conditioning, Psychological; Cues; Dopamine Agonists; Dopamin | 2009 |
Diagnosis and treatment of comorbidities of Tourette's syndrome and bipolar disorder in a 10-year-old boy.
Topics: Antipsychotic Agents; Bipolar Disorder; Child; Comorbidity; Humans; Lithium; Male; Risperidone; Tour | 2009 |
Treatment practices in Tourette syndrome: the European perspective.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Anxiety; Aripiprazole; Atomoxetine Hydrochloride | 2012 |
Case study of circadian rhythm sleep disorder following haloperidol treatment: reversal by risperidone and melatonin.
Topics: Adult; Antipsychotic Agents; Chronotherapy; Circadian Rhythm; Haloperidol; Humans; Male; Melatonin; | 2002 |
Depression and dysphoria in adult and adolescent patients with Tourette's disorder treated with risperidone.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Depression; Depressive Disorder, Major; Dose-Response | 2002 |
Obsessive-Compulsive disorder, Tourette's disorder, or pediatric autoimmune neuropsychiatric disorders associated with Streptococcus in an adolescent? Diagnostic and therapeutic challenges.
Topics: Adolescent; Antipsychotic Agents; Autoimmune Diseases; Citalopram; Clinical Laboratory Techniques; D | 2003 |
Stimulant-atypical antipsychotic interaction and acute dystonia.
Topics: Adolescent; Aggression; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Bipolar | 2005 |
Effectiveness and safety of risperidone for children and adolescents with chronic tic or tourette disorders in Korea.
Topics: Adolescent; Analysis of Variance; Child; Chronic Disease; Female; Humans; Korea; Male; Risperidone; | 2005 |
New-onset Tourette syndrome following human growth hormone therapy.
Topics: Body Height; Brain; Child; Dopamine Antagonists; Growth Disorders; Human Growth Hormone; Humans; Mag | 2007 |
Transient ischemic attack with risperidone and clonidine.
Topics: Adrenergic alpha-Agonists; Antipsychotic Agents; Child; Clonidine; Diagnosis, Differential; Drug Adm | 2007 |
Risperidone for Tourette's syndrome.
Topics: Adult; Antipsychotic Agents; Humans; Isoxazoles; Male; Piperidines; Risperidone; Severity of Illness | 1994 |
Serotonin-dopamine antagonist and Gilles de la Tourette's syndrome: an open pilot dose-titration study with risperidone.
Topics: Adult; Antipsychotic Agents; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Administra | 1994 |
Risperidone treatment for a Tourette's disorder patient with comorbid obsessive-compulsive disorder.
Topics: Adult; Antipsychotic Agents; Comorbidity; Depressive Disorder; Drug Therapy, Combination; Fluoxetine | 1995 |
Risperidone in Gilles de la Tourette syndrome.
Topics: Antipsychotic Agents; Humans; Isoxazoles; Male; Middle Aged; Piperidines; Risperidone; Tourette Synd | 1995 |
Risperidone treatment of children and adolescents with chronic tic disorders: a preliminary report.
Topics: Adolescent; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Child; Chronic Dise | 1995 |
Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disorders.
Topics: Adult; Drug Therapy, Combination; Female; Hospital Records; Humans; Male; Middle Aged; Obsessive-Com | 1997 |
Erythromycin interaction with risperidone or clomipramine in an adolescent.
Topics: Acne Vulgaris; Adolescent; Clomipramine; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2D6; Erythromy | 1996 |
A possible tetracycline-risperidone-sertraline interaction in an adolescent.
Topics: Adolescent; Anti-Bacterial Agents; Antidepressive Agents, Second-Generation; Antipsychotic Agents; D | 1999 |
Risperidone treatment of aggressive behavior in children with Tourette syndrome.
Topics: Adolescent; Aggression; Antipsychotic Agents; Child; Child, Preschool; Female; Humans; Male; Retrosp | 2000 |
Extrapyramidal symptoms with ritonavir/indinavir plus risperidone.
Topics: Acquired Immunodeficiency Syndrome; Adult; Basal Ganglia Diseases; Cytochrome P-450 CYP2D6 Inhibitor | 2002 |